Advertisement
Screener

Citius Oncology, Inc. (CTOR) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Citius Oncology, Inc. Stock-Based Compensation

Citius Oncology, Inc. (CTOR) reported Stock-Based Compensation of $3.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-14

  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.56M, a 67.55% increase year-over-year.
  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.53M, a 68.86% increase year-over-year.
  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.96M, a 118.75% increase year-over-year.
  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.30M, a 37.79% increase year-over-year.
  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $8.32M, a 10.96% increase from fiscal 2024.
  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $7.50M, a 281.52% increase from fiscal 2023.
  • Citius Oncology, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.97M.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$3.56M
10-Q · filed 2026-08-14
$7.09M
derived: sum of 2 quarters · filed 2026-08-14
$11.04M
10-Q · filed 2026-08-14
$13.34M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$3.53M
10-Q · filed 2026-05-15
$7.48M
10-Q · filed 2026-05-15
$9.78M
derived: sum of 3 quarters · filed 2026-05-15
$11.91M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$3.96M
10-Q · filed 2026-02-13
$6.25M
derived: sum of 2 quarters · filed 2026-02-13
$8.38M
derived: sum of 3 quarters · filed 2026-08-14
$10.47M
derived: sum of 4 quarters · filed 2026-08-14
2025-09-30$2.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23
$4.42M
derived: sum of 2 quarters · filed 2026-08-14
$6.51M
derived: sum of 3 quarters · filed 2026-08-14
$8.32M
10-K · filed 2025-12-23
2025-06-30$2.13M
10-Q · filed 2026-08-14
$4.21M
derived: sum of 2 quarters · filed 2026-08-14
$6.02M
10-Q · filed 2026-08-14
$7.69M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$2.09M
10-Q · filed 2026-05-15
$3.90M
10-Q · filed 2026-05-15
$5.56M
derived: sum of 3 quarters · filed 2026-05-15
$7.52M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$1.81M
10-Q · filed 2026-02-13
$3.48M
derived: sum of 2 quarters · filed 2026-02-13
$5.43M
derived: sum of 3 quarters · filed 2026-02-13
$7.39M
derived: sum of 4 quarters · filed 2026-02-13
2024-09-30$1.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23
$3.62M
derived: sum of 2 quarters · filed 2025-12-23
$5.58M
derived: sum of 3 quarters · filed 2025-12-23
$7.50M
10-K · filed 2025-12-23
2024-06-30$1.96M
10-Q · filed 2025-08-12
$3.91M
derived: sum of 2 quarters · filed 2025-08-12
$5.83M
10-Q · filed 2025-08-12
2024-03-31$1.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14
$3.87M
10-Q · filed 2025-05-14
2023-12-31$1.92M
10-Q · filed 2025-02-14
2023-09-30$1.97M
10-K · filed 2024-12-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Anixa Biosciences Inc (ANIX)United States$0.096B
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
ProMIS Neurosciences Inc. (PMN)$0.102B
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Equillium, Inc. (EQ)United States$0.109B-11.27